Potentiation of cis-diamminedichloroplatinum nephrotoxicity by amikacin in rats.

abstract：INTRODUCTION:High cut-off dialysis, increasingly used in multiple myeloma patients, is susceptible to influence anticancer drug elimination. We report about lenalidomide disposition in a patient on high cut-off dialysis for renal failure secondary to myeloma cast nephropathy. METHODS:The patient received a higher dosa...

journal_title：Cancer chemotherapy and pharmacology

authors： Dao K,Lu Y,Peer CJ,Figg WD,Stadelmann R,Burnier M,Buclin T,Kissling S

更新日期：2017-01-01 00:00:00

abstract：PURPOSE:The phosphoinositide-3-kinase (PI3K) pathway is the frequently altered in human cancer. This has led to the development and study of novel PI3K inhibitors for targeted therapy and also to overcome resistance to radiotherapy. METHOD:The anti-tumour effects of PI3K inhibitors (PI-828, PI-103 and PX-866) in terms...

journal_title：Cancer chemotherapy and pharmacology

authors： Aggarwal S,John S,Sapra L,Sharma SC,Das SN

更新日期：2019-03-01 00:00:00

abstract：PURPOSE:P-glycoprotein is a 170-kDa plasma membrane multidrug transporter that actively exports cytotoxic substances from cells. Overexpression of P-glycoprotein by tumor cells is associated with a multidrug-resistant phenotype. Immunosuppressive agents such as cyclosporins and macrolides, have been shown to attenuate ...

journal_title：Cancer chemotherapy and pharmacology

authors： Mealey KL,Barhoumi R,Burghardt RC,McIntyre BS,Sylvester PW,Hosick HL,Kochevar DT

更新日期：1999-01-01 00:00:00

abstract：:The plasma pharmacokinetics of the anti-tumor antibiotic geldanamycin (GM: NSC 122750), a naturally occurring benzoquinoid ansamycin, was characterized in mice and a beagle dog. Concentrations of GM well above 0.1 microgram/ml, which was typically effective against neoplastic cell lines responsive to the drug in vitro...

journal_title：Cancer chemotherapy and pharmacology

authors： Supko JG,Hickman RL,Grever MR,Malspeis L

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:To evaluate the safety and efficacy of paclitaxel in elderly patients with advanced non-small-cell lung cancer (NSCLC). METHODS:We compared the toxicity, response, survival and pharmacokinetic parameters between patients between 70 and 75 years of age (elderly group) and those under 70 years of age (younger gr...

journal_title：Cancer chemotherapy and pharmacology

authors： Nakamura Y,Sekine I,Furuse K,Saijo N

更新日期：2000-01-01 00:00:00

abstract：PURPOSE:The activity of 5-fluorouracil (5-FU) against colon cancer is enhanced by leucovorin and the combination of 5-FU and levamisole has activity in the adjuvant treatment of colonic malignancies. The combination of 5-FU with both leucovorin and levamisole may provide additional benefit in the treatment of colon can...

journal_title：Cancer chemotherapy and pharmacology

authors： Cleary JF,Arzoomanian R,Alberti D,Feierabend C,Storer B,Witt P,Carbone P,Wilding G

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:Decitabine is a nucleoside analog used in the treatment for myelodysplastic syndrome. The compound requires intracellular conversion to its triphosphate to become active. Decitabine triphosphate has, however, never been quantified in peripheral blood mononuclear cells (PBMCs) from patients. METHOD:This article...

journal_title：Cancer chemotherapy and pharmacology

authors： Jansen RS,Rosing H,Wijermans PW,Keizer RJ,Schellens JH,Beijnen JH

更新日期：2012-06-01 00:00:00

abstract：:Anticipating the renewed clinical trial of the antitumor agent 2-amino-1,3,4-thiadiazole (AT, NSC-4728), we have studied the pharmacologic fate of AT-5-14C in beagle dogs. The drug was only minimally metabolized in 5 h; the radioactivities in the urine, and particularly in the plasma, resided almost entirely in unchan...

journal_title：Cancer chemotherapy and pharmacology

authors： Lu K,Loo TL

更新日期：1980-01-01 00:00:00

abstract：PURPOSE:Artemisinins are now established drugs for treatment of malaria. These agents have been shown to possess impressive anti-cancer properties. We have investigated the role of artemisone (ATM), a novel derivative of artemisinin (ART) in a cancer setting both alone and in combination with established chemotherapeut...

journal_title：Cancer chemotherapy and pharmacology

authors： Gravett AM,Liu WM,Krishna S,Chan WC,Haynes RK,Wilson NL,Dalgleish AG

更新日期：2011-03-01 00:00:00

abstract：BACKGROUND:Rapidly dividing tumor cells have an increased demand for nutrients to support their characteristic unabated growth; this demand is met by an increased availability of nutrients such as amino acids through vasculogenesis and by the enhanced cellular entry of nutrients through the upregulation of specific tra...

journal_title：Cancer chemotherapy and pharmacology

authors： Trojel-Hansen C,Erichsen KD,Christensen MK,Jensen PB,Sehested M,Nielsen SJ

更新日期：2011-07-01 00:00:00

abstract：PURPOSE:Midostaurin (PKC412) is a multitargeted tyrosine kinase inhibitor of FMS-like tyrosine kinase 3 receptor (FLT3), c-KIT, and other receptors. Midostaurin is active in patients with acute myeloid leukemia and systemic mastocytosis. Although no substantive risk for cardiac abnormalities has been observed with mido...

journal_title：Cancer chemotherapy and pharmacology

authors： del Corral A,Dutreix C,Huntsman-Labed A,Lorenzo S,Morganroth J,Harrell R,Wang Y

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND:Ovarian cancer is one of the most frequently fatal gynecological cancers because most cases are diagnosed at an advanced stage. Loss of growth control and a marked resistance to apoptosis are considered major mechanisms driving tumor progression. Little is known about the effect of various treatment regimens...

journal_title：Cancer chemotherapy and pharmacology

authors： Dutta T,Sharma H,Kumar L,Dinda AK,Kumar S,Bhatla N,Singh N

更新日期：2005-10-01 00:00:00

abstract：:A total of 20 adults patients presenting with previously untreated lymphoblastic lymphoma underwent an intensive chemotherapy protocol. Either the BACOP or the m-BACOD regimen was used for induction. If the patients achieved a complete clinical remission (CR) after three courses, they were given intensive consolidatio...

journal_title：Cancer chemotherapy and pharmacology

authors： Liang R,Todd D,Chan TK,Chiu E,Lie A,Ho FC,Loke SL

更新日期：1991-01-01 00:00:00

abstract：:N2,N4,N6-Trihydroxymethyl-N2,N4,N6-trimethylmelamine (Trimelamol) is a water-soluble synthetic s-triazine which, unlike hexamethylmelamine (HMM) and pentamethylmelamine (PMM), does not require metabolic activation. The physico-chemical characteristics of Trimelamol were studied with the aim of overcoming the problems ...

journal_title：Cancer chemotherapy and pharmacology

authors： Rutty CJ,Judson IR,Abel G,Goddard PM,Newell DR,Harrap KR

更新日期：1986-01-01 00:00:00

abstract：PURPOSE:To evaluate the effect of front-line chemotherapy on CK-19mRNA+ circulating tumor cells (CTCs) and their relevance in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS:The presence of CK-19mRNA+ CTCs was assessed using a real-time RT-PCR assay in 298 previously untreated patients with MBC befo...

journal_title：Cancer chemotherapy and pharmacology

authors： Georgoulias V,Apostolaki S,Bozionelou V,Politaki E,Perraki M,Georgoulia N,Kalbakis K,Kotsakis A,Xyrafas A,Agelaki S,Mavroudis D

更新日期：2014-12-01 00:00:00

abstract：:CD-1 mice are commonly used in oncology metabolism and toxicity to support drug discovery and development and to examine drug metabolism and toxicity properties of new chemical entities. On the other hand, athymic nude mice are the preferred animals to investigate tumor growth inhibition. Therefore, a frequently asked...

journal_title：Cancer chemotherapy and pharmacology

authors： Martignoni M,de Kanter R,Moscone A,Grossi P,Monshouwer M

更新日期：2005-02-01 00:00:00

abstract：PURPOSE:The histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances cisplatin [cis-diammine dichloroplatinum (II)] (CDDP)-induced apoptosis in the oral squamous cell carcinoma (OSCC) cell line by complex, multifunctional mechanisms. We investigated the role of endoplasmic reticulum (ER) stress i...

journal_title：Cancer chemotherapy and pharmacology

authors： Suzuki M,Endo M,Shinohara F,Echigo S,Rikiishi H

更新日期：2009-11-01 00:00:00

abstract：PURPOSE:The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer. METHODS:A total...

journal_title：Cancer chemotherapy and pharmacology

authors： Pilancı KN,Saglam S,Okyar A,Yucel S,Pala-Kara Z,Ordu C,Namal E,Ciftci R,Iner-Koksal U,Kaytan-Saglam E

更新日期：2016-07-01 00:00:00

abstract：PURPOSE:Based on our mouse xenograft model demonstrating that intermittent high-dose gefitinib sensitizes tumors to subsequent treatment with taxanes, we initiated this phase I trial to explore docetaxel in combination with escalating doses of intermittent gefitinib (Iressa) given prior to docetaxel. METHODS:This was ...

journal_title：Cancer chemotherapy and pharmacology

authors： Fury MG,Solit DB,Su YB,Rosen N,Sirotnak FM,Smith RP,Azzoli CG,Gomez JE,Miller VA,Kris MG,Pizzo BA,Henry R,Pfister DG,Rizvi NA

更新日期：2007-03-01 00:00:00

abstract：PURPOSE:Cyclosporine A (CyA) is able to inhibit P-glycoprotein (P-gp) and to increase cytotoxicity of some anticancer drugs, including etoposide. However, the effect of CyA on the distribution of etoposide in normal tissues, which could affect their toxicity, has not been studied extensively. The purpose of this study ...

journal_title：Cancer chemotherapy and pharmacology

authors： Cárcel-Trullols J,Torres-Molina F,Araico A,Saadeddin A,Peris JE

更新日期：2004-08-01 00:00:00

abstract：:The purpose of this trial was to minimize local inflammation caused by intravesical instillation of antitumor agents, especially Adriamycin, in the treatment of bladder tumor. Tranexamic acid was chosen as the solvent vehicle for Adriamycin and IV bolus injection of an antiallergic drug, Stronger neo-minophagen C, was...

journal_title：Cancer chemotherapy and pharmacology

authors： Ohi Y,Okamoto K,Kawabata T,Hanafusa A,Fai CY,Kakinoki T,Kawahara M,Asechi S,Sakamoto N,Nagata S

更新日期：1983-01-01 00:00:00

abstract：PURPOSE:Cyclophosphamide is a cytotoxic chemotherapy drug that causes severe damages to hematopoietic and gastrointestinal systems. The aim of this study is to evaluate the protective effects of recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) on chemotherapy-induced mucositis (CIM) in a murine model of c...

journal_title：Cancer chemotherapy and pharmacology

authors： Xiang D,Guo Y,Zhang J,Gao J,Lu H,Zhu S,Wu M,Yu Y,Han W

更新日期：2011-06-01 00:00:00

abstract：PURPOSE:We conducted a phase II trial to evaluate the efficacy and safety of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for advanced non-squamous non-small-cell lung cancer (NSCLC). METHODS:Patients with advanced or recurrent untreated non-squamous NSCLC received ...

journal_title：Cancer chemotherapy and pharmacology

authors： Koba T,Minami S,Nishijima-Futami Y,Masuhiro K,Kimura H,Futami S,Yaga M,Mori M,Kagawa H,Uenami T,Kohmo S,Otsuka T,Yamamoto S,Komuta K,Kijima T

更新日期：2018-07-01 00:00:00

abstract：PURPOSE:To compare serum and urine levels of tamoxifen and metabolites after a loading dose and at the steady state. METHODS:A loading dose of 160 mg of tamoxifen was given to 14 patients with advanced breast cancer. Thereafter a regular daily dose of 30 mg of tamoxifen was given. Serum and urine levels of tamoxifen a...

journal_title：Cancer chemotherapy and pharmacology

authors： de Vos D,Slee PH,Briggs RJ,Stevenson D

更新日期：1998-01-01 00:00:00

abstract：:The effect of acetazolamide (A.A.) on the antineoplastic activity of 1-phthalidyl 5-fluorouracil (PH-FU) against rat and mouse solid tumors was examined. A.A., an inhibitor of liver PH-FU hydrolase, had no antitumor activity but greatly enhanced the activity of PH-FU when coadministered. The potentiation was evaluated...

journal_title：Cancer chemotherapy and pharmacology

authors： Kasai H,Tonda K,Hirata M

更新日期：1986-01-01 00:00:00

abstract：:We propose a mathematical model that takes into account a classical maximum tolerated dose (MTD) chemotherapy regimen (whose primary targets are the tumor cells) as well as a metronomic chemotherapy regimen (whose primary targets are the tumor endothelial cells) for the administration of temozolomide (Temodal(®)) in o...

journal_title：Cancer chemotherapy and pharmacology

authors： Faivre C,Barbolosi D,Pasquier E,André N

更新日期：2013-04-01 00:00:00

abstract：:The stability of solutions of the antitumour antimetabolites, vinca alkaloids, podophyllotoxins, interferons, steroids and platinum drugs as well as maytansine, asparaginase, amsacrine, flavone-8-acetic acid, mitoguazone, and N-phosphonoacetyl-L-aspartate (PALA) is reviewed. Much of the published work has been done wi...

journal_title：Cancer chemotherapy and pharmacology

authors： Bosanquet AG

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:The aim of this study was to investigate typical population pharmacokinetic (PK) parameters, potential covariates, and interindividual and residual variabilities of PI-88, a heparanase endoglycosidase enzyme inhibitor being developed for the treatment of cancer. METHODS:A population PK model of PI-88 was devel...

journal_title：Cancer chemotherapy and pharmacology

authors： Hudachek SF,Eckhardt SG,Hicks B,Gustafson DL

更新日期：2010-03-01 00:00:00

abstract：:The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin (BCG) for prophylaxis of recurrence of superficial bladder cancer (pTa, pT1) were investigated in 29 patients aged a median of 70 years between January of 1991 and May of 1993. The patients received intravesical instillation of...

journal_title：Cancer chemotherapy and pharmacology

authors： Uekado Y,Hirano A,Shinka T,Ohkawa T

更新日期：1994-01-01 00:00:00

abstract：:AspCNU and SarCNU are two amino acid amide congeners (L-asparaginamide and sarcosinamide congeners) of chloroethylnitrosoureas. The in vitro myelotoxicity of these agents compared with BCNU at 1-8 micrograms/ml was determined in bone marrow cells from normal volunteers in the CFU-C assay. AspCNU and SarCNU were signif...

journal_title：Cancer chemotherapy and pharmacology

authors： Panasci LC,Dufour M,Chevalier L,Isabel G,Lazarus P,McQuillan A,Arbit E,Brem S,Feindel W

更新日期：1985-01-01 00:00:00